The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.

Launched by QING SU · Mar 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a supplement called nicotinamide mononucleotide (NMN) might help improve the immune system and metabolic health in middle-aged and older adults who have certain metabolic disorders, such as pre-diabetes or fatty liver disease. As we age, our immune system can weaken, and this study aims to see if NMN can help slow down this process and improve overall health. Participants will be monitored for changes in body composition, sugar and fat levels in the blood, and other health indicators over time.

To be eligible for the trial, participants should be between 50 and 70 years old, have a body mass index (BMI) of 25 or higher, and have at least one metabolic condition like pre-diabetes or fatty liver disease. It’s important that those interested in joining can commit to follow-up visits and have signed consent to participate. However, individuals with certain health issues, like severe heart disease or active infections, will not be able to join. This trial is not yet recruiting participants, but it aims to find new ways to support the health of older adults facing metabolic challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 50-70 years with overweight or obesity (BMI 24kg/m2);
• • 2. At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c \<7% without glucose-lowering drug therapy;
• • 3. Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
• Exclusion Criteria:
• • 1. Patients with tumours;
• • 2. Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
• • 3. Severe cardiovascular disease or cardiac insufficiency;
• • 4. Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg;
• • 5. Chronic obstructive pulmonary disease;
• • 6. Chronic active hepatitis or cirrhosis;
• • 7. Chronic renal insufficiency;
• • 8. Stroke patients
• • 9. Severe haematological diseases;
• • 10. Infectious diseases;
• • 11. Mental illness;
• • 12. Other conditions that, in the opinion of the investigator, may affect the results of the study;
• • 13. Those who have used NMN or other anti-aging agents within six months.
• • 14. Premenopausal woman
• • 15. ALT, AST values are more than three times higher than the upper limit of the normal reference range